InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
uniQure is delivering on the promise of gene therapy -- single treatments with pot...
uniQure is delivering on the promise of gene th...
Dentsply Sirona is the worldâs largest manufacturer of professional dental produ...
Dentsply Sirona is the worldâs largest manufa...
Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on o...
Immuron Ltd is a publicly listed Australian bio...
Sol-Gel is a clinical-stage specialty pharmaceutical company focused on developing...
Sol-Gel is a clinical-stage specialty pharmaceu...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company th...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a ...
CohBar, Inc. is a leader in the research and development of mitochondria based the...
CohBar, Inc. is a leader in the research and de...
argenx is a clinical-stage biotechnology company developing a deep pipeline of dif...
argenx is a clinical-stage biotechnology compan...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
Equillium is a biotechnology company leveraging deep understanding of immunobiolog...
Equillium is a biotechnology company leveraging...
We are a clinical-stage biopharmaceutical company focused on the development of no...
We are a clinical-stage biopharmaceutical compa...
Join the National Investor Network and get the latest information with your interests in mind.